Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17129-34. doi: 10.1073/pnas.1112122108. Epub 2011 Oct 3.
The deleted in liver cancer 1 (DLC1) tumor suppressor gene, which is frequently inactivated in cancer, encodes a Rho-GAP (GTPase activating protein) focal adhesion protein whose negative regulation of Rho-GTPases is necessary but not sufficient for its full tumor suppressor activity. Here, we report that DLC1 forms a complex with two prooncogenic focal adhesion proteins, talin and the focal adhesion kinase (FAK). We identified an 8-aa sequence (residues 469LDDILYHV476) in DLC1 and designated it an LD-like motif, because it shares homology with the LD motifs of paxillin. This motif was necessary for DLC1 binding to talin and FAK, because a DLC1 mutant, from which six of the residues have been deleted, and another mutant carrying amino acid substitutions in three of the residues are deficient for binding both proteins and localization of DLC1 to focal adhesions. FAK binding was independent of talin and vice versa. In bioassays, both DLC1 mutants were less active than wild-type (WT) DLC1, although the ability of the mutants to negatively regulate overall Rho-GTP was not impaired. We conclude that the LD-like motif, which binds talin and FAK, is required for the full tumor suppressor activity of DLC1 and contributes to the association of DLC1 with focal adhesions.
肝癌缺失基因 1(DLC1)是一种肿瘤抑制基因,其在癌症中经常失活,编码一种 Rho-GAP(GTPase 激活蛋白),其对 Rho-GTP 的负调控是其完全肿瘤抑制活性所必需的,但不是充分的。在这里,我们报告 DLC1 与两种致癌性粘着斑蛋白,talin 和粘着斑激酶(FAK)形成复合物。我们在 DLC1 中鉴定出一个 8 个氨基酸序列(残基 469LDDILYHV476),并将其命名为 LD 样基序,因为它与粘着斑蛋白 paxillin 的 LD 基序具有同源性。该基序对于 DLC1 与 talin 和 FAK 的结合是必需的,因为一个 DLC1 突变体,其中六个残基被删除,另一个突变体在三个残基中携带氨基酸取代,对于结合这两种蛋白和 DLC1 到粘着斑的定位都是有缺陷的。FAK 结合不依赖于 talin,反之亦然。在生物测定中,两种 DLC1 突变体的活性均低于野生型(WT)DLC1,尽管突变体负调控整体 Rho-GTP 的能力没有受损。我们得出结论,该 LD 样基序,它结合 talin 和 FAK,是 DLC1 完全肿瘤抑制活性所必需的,并有助于 DLC1 与粘着斑的关联。